YLYuyu Li

Yuyu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuyu Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Jiaqi Yu

    Department of Cardiology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China

    2 shared publications
  • Zhechuan Jin

    Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China

    2 shared publications
  • Biao Xu

    Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing 210008, China

    1 shared publication
  • Chongming Wu

    School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    1 shared publication
  • Dinghong Liu

    Cardiac and Vascular Center, Anhui No.2 Provincial People's Hospital, Hefei 230041, Anhui Province, China

    1 shared publication
  • Guangpu Fan

    Cardiac and Vascular Center, Anhui No.2 Provincial People's Hospital, Hefei 230041, Anhui Province, China

    1 shared publication

Latest Publications

  • Open Access

    A biohybrid nanovesicle hijacks inflammatory chemotaxis to deliver colchicine for myocardial infarction therapy

    by Xiangyong Hu, Liping Du, Hongju Xiang, Yuyu Li, Zhixiong Liao, Jiaqi Yu

    Introduction: Myocardial infarction (MI) triggers an excessive inflammatory response that drives adverse cardiac remodeling. Although colchicine has shown clinical promise, its narrow therapeutic window and lack of target specificity limit its efficacy. To address these limitations, we developed a biohybrid nanovesicle (MM‐LP@COL) that encapsulates colchicine, aiming to leverage natural inflammatory tropism for site-specific drug delivery. Methods: MM‐LP@COL nanovesicles were fabricated by fusing macrophage membranes with liposomes. Physicochemical characterization was performed using DLS, TEM, and FRET analysis. Cytokine‐scavenging capacity was evaluated in vitro by ELISA. In a murine MI model, mice were treated with PBS, free colchicine, LP@COL, or MM‐LP@COL. Immune cell populations in blood, bone marrow, and spleen were analyzed by high‐dimensional flow cytometry (UMAP). Cardiac function and tissue remodeling were assessed by echocardiography and histology. Results: MM‐LP@COL formed uniform spherical nanovesicles (∼200 nm) and demonstrated potent, dose‐dependent neutralization of multiple pro‐inflammatory cytokines in vitro , along with reduced circulating cytokine levels in MI mice. High‐dimensional cytometric analysis revealed that treatment significantly reduced neutrophil infiltration across key immune organs, including blood, bone marrow, and spleen. These effects translated into improved left ventricular function, reduced myocardial inflammation, and attenuated cardiomyocyte hypertrophy. Discussion: This study demonstrates that the macrophage-inspired nanovesicle system constitutes a potent and targeted combinatorial therapy for post-infarction inflammation and repair.

  • Top Cited Papers
    Open Access

    Role of gut microbiota and derived metabolites in cardiovascular diseases

    by Jiaqi Yu, Ya-Nan Yang, Weiyao Chen, Jiaxin Hu, Zhechuan Jin, Chongming Wu, Yuyu Li


  • Open Access

    Artificial lipids and macrophage membranes coassembled biomimetic nanovesicles for thoracic aortic dissection treatment

    by Yanlin Gao, Li Rong, Jing Cui, Wei Cheng, Lin Fu, Guangpu Fan, Haiyan Wang, Jiaqi Yu, Zhen Li, Dinghong Liu, et al.


  • Open Access

    Colchicine Attenuates Microvascular Obstruction after Myocardial Ischemia-Reperfusion Injury by Inhibiting the Proliferation of Neutrophil in Bone Marrow

    by Ying Tan, Xue Bao, Yuyu Li, Guo Song, He Lu, Xuan Sun, Rong Gu, Lina Kang, Biao Xu

    Purpose: Complete and rapid recanalization of blood flow by percutaneous coronary intervention (PCI) is the most effective intervention for patients with ST-segment elevation myocardial infarction (STEMI). However, myocardial ischemia/reperfusion (I/R) injury leads to microvascular obstruction (MVO), limiting its efficacy. Colchicine can reduce myocardial I/R injury, but its effect on MVO is unclear. Hence, this study aimed to assess the role and mechanism of colchicine on MVO. Methods: Clinical data on STEMI patients with PCI were collected and risk factors related to MVO were analyzed. The rat myocardial I/R model was established to evaluate the MVO by thioflavin S staining. The myocardial I/R model of mice was treated with PBS or colchicine at the reperfusion. The effect of colchicine on cardiomyocyte apoptosis after I/R was evaluated by TUNEL and expression of cleaved caspase-3. ROS levels were detected in H9c2 cells to evaluate the colchicine effect on myocardial oxidative stress. Moreover, the mechanism through which colchicine attenuated MVO was examined using flow cytometry, WB, ELISA, immunohistochemistry, bioinformatics analysis, and immunofluorescence. Results: Multivariate analysis showed that elevated neutrophils were associated with extensive MVO. Colchicine could attenuate MVO and reduce neutrophil recruitment and NETs formation after myocardial I/R. In addition, colchicine inhibited cardiomyocyte apoptosis in vivo and ROS levels in vitro. Furthermore, colchicine inhibited neutrophil proliferation in the bone marrow (BM) by inhibiting the S100A8/A9 inflammatory signaling pathway. Conclusions: Colchicine attenuated MVO after myocardial I/R injury by inhibiting the proliferation of neutrophils in BM through the neutrophil-derived S100A8/A9 inflammatory signaling pathway.